SkylineDx to Showcase Innovative Research at Oncology Congress
SkylineDx, a leader in molecular diagnostics for oncology, inflammatory, and infectious diseases, has announced its participation in a significant upcoming event. The company will present late-breaking data on its pioneering Merlin test during a prominent session and a poster presentation at the Society for Melanoma Research (SMR). This event is highly anticipated by experts and stakeholders in the field.
Details of the Oral Presentation
One of the highlights for SkylineDx at the congress will be an oral presentation during Plenary Session 10, focusing on late-breaking clinical abstracts. This presentation will detail the findings of the MERLIN_001 Trial, which examines the clinicopathological and gene expression profile tests to predict sentinel node status in T1-T3 cNO melanoma.
Presentation Schedule
The oral presentation is scheduled for Sunday, and will begin at 10:45 AM CDT. It will be led by Dr. Vernon K. Sondak, Department Chair of Cutaneous Oncology at Moffitt Cancer Center, who will share key insights derived from groundbreaking research in melanoma treatment.
Poster Presentation Insights
Additionally, SkylineDx will present a poster titled CP-GEP Identifies T1a Melanoma Patients at Risk of Sentinel Lymph Node Metastasis. This poster session will take place on Friday, running from 1:00 to 2:00 PM CDT, and will be presented by Dr. Alex Meves from the Mayo Clinic. This session promises to shed light on new ways to identify melanoma patients who are at risk for metastasis, enhancing the clinical approach to treatment.
Key Features of the CP-GEP Model
The CP-GEP, or the Merlin test, represents a significant advancement in predictive modeling for melanoma patients. This non-invasive model integrates clinicopathological information with gene expression profiles to identify patients who are at low risk of nodal metastasis. Consequently, these patients may avoid unnecessary surgical procedures, such as sentinel lymph node biopsies, reducing the physical burden of treatment.
About SkylineDx and Its Innovations
SkylineDx's commitment to innovation is emblematic of its role in transforming the landscape of cancer diagnostics. The company is not just focused on product development but also on bridging the gap between academic findings and practical diagnostic tools that can enhance clinical utility. Their collaborative efforts within the medical community support the development of high-performance diagnostic products, enabling healthcare professionals to provide individualized treatment plans to patients based on specific test outcomes.
Furthermore, the Merlin test has already been launched in various markets, including the United States and Europe. In the U.S., Tempus is responsible for commercializing the Tempus Merlin test. In addition, Quest Diagnostics has introduced its own version of the CP-GEP model under the name MelaNodal Predict™, showcasing the widespread adoption and recognition of this innovative diagnostic tool.
Conclusion: An Important Gathering for Melanoma Research
The upcoming Society for Melanoma Research congress is a crucial event where leading researchers and industry professionals will convene to discuss advancements in melanoma research and treatment options. SkylineDx is proud to contribute to this dialogue and share its findings from the Merlin test. The data presented could reshape how clinicians handle melanoma diagnostics and treatment strategies, ensuring better outcomes for patients.
Frequently Asked Questions
What is the Merlin test?
The Merlin test is a non-invasive prediction model designed to assess the risk of metastasis in melanoma patients by combining clinical data with gene expression profiles.
Who will present the findings at the congress?
Dr. Vernon K. Sondak will present the oral findings, while Dr. Alex Meves will deliver the poster presentation on the Merlin test.
When will the oral presentation take place?
The oral presentation is scheduled for Sunday at 10:45 AM CDT during the Plenary Session 10.
What is the significance of the CP-GEP model?
The CP-GEP model helps identify patients at low risk for sentinel lymph node metastasis, potentially allowing them to skip invasive biopsy procedures.
Where is SkylineDx based?
SkylineDx is headquartered in Rotterdam, the Netherlands, with an operational base and laboratory in San Diego, California.
